Agomelatine, available as Valdoxan and Thymanax, is an atypical antidepressant that belongs to a class of non-controlled prescription drugs. Agomelatine could allegedly treat major depressive episodes in adults and is sold in many countries such as those in Europe. It is known for its potential to prevent depression relapse and improve sleep patterns. However, the US FDA does not approve this chemical as a form of treatment.
Extensive therapeutic trials have demonstrated the efficacy of Agomelatine in both short-term and long-term treatment of major depression. Notably, it has shown promising results in early improvement of sleep quality and daytime function, preservation of sexual function, absence of weight gain, and lack of withdrawal symptoms upon discontinuation.
Since Agomelatine is not an approved medication in the USA, buy Agomelatine for laboratory research use only.
Agomelatine Product Details
Agomelatine, developed in 1997, acts as an agonist of the melatonin receptors (MT1 and MT2) and an antagonist of the serotonin receptors (5HTC). It received authorization for medical use in the European Union in 2009 and in Australia in 2010. However, the US FDA did not grant Agomelatine a similar status. This is because Agomelatine did not appear to be any more effective than other medications for depression in 2012.
However, current trials have demonstrated the potential effectiveness of Agomelatine as a treatment for major depressive disorder. It has also shown promise in preventing depression relapse. Additionally, Agomelatine exhibits favorable tolerability compared to commonly prescribed antidepressants.
In animal models of depression, Agomelatine has exhibited anxiolytic properties and the ability to resynchronize circadian rhythms in a dose-dependent manner. These findings suggest that Agomelatine may have the potential to promote sleep and restore the normal functioning of the biological clock in humans.
- CAS Number 138112-76-2
- Molar Mass 243.3 g/mol
- Chemical Structure C15H17NO2
- IUPAC Name N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
Key Features of Agomelatine
- 98% Purity
- Sold for research purposes only
Potential Benefits of Agomelatine
Agomelatine and Cognition
In a 2017 animal study, Agomelatine exhibited effectiveness in alleviating stress-induced cognitive impairments in mice. It also reversed stress-induced gene-related effects. Additionally, Agomelatine significantly improved memory impairments caused by stress in mice. [R]
Another study focused on investigating the chronic effects of Agomelatine administration on the cognitive performance of rats. The results demonstrated that the memory performance of Agomelatine-treated rats during one of the trials was significantly better compared to the control group. Furthermore, Agomelatine-treated animals showed improved learning abilities, indicating beneficial effects on cognitive parameters. [R]
Agomelatine and Sexual Function
In a large-scale, randomized, placebo-controlled trial, Agomelatine showed a lower risk of deterioration in sexual function compared to Venlafaxine, a first-line antidepressant. The rate of sexual dysfunction was similar between the placebo and Agomelatine groups, suggesting a potential advantage of Agomelatine over other antidepressants in terms of sexual side effects. [R]
Agomelatine and Major Depressive Disorder
Ten placebo-controlled trials were conducted to investigate the short-term efficacy of Agomelatine in test subjects with major depressive disorder. Results from these trials, spanning over 6 to 8 weeks, revealed significant efficacy in 6 out of 10 trials, indicating the potential effectiveness of Agomelatine. [R]
A comprehensive meta-analysis of 20 trials involving over 7,400 test subjects concluded that Agomelatine is an effective antidepressant with similar efficacy to standard antidepressants. Importantly, the analysis also indicated that Agomelatine may pose a relatively low risk of sexual side effects. [R]
Furthermore, a placebo-controlled trial demonstrated that Agomelatine potentially successfully prevented relapse in more than two-thirds (78%) of the test subjects. The incidence of relapse during the 6-month follow-up period was notably lower for Agomelatine (22%) compared to placebo (47%).
Agomelatine and Alzheimer’s Disease
A study conducted on rats investigated the potential neuroprotective effect of Agomelatine in Alzheimer’s disease (AD). The findings demonstrated that Agomelatine attenuated spatial memory deficits, reduced amyloid-B deposition, and mitigated neuroinflammation in the mice’s hippocampus. These results suggest that Agomelatine holds promise as a candidate for AD therapy. [R]
Agomelatine and Anxiety
A study conducted in 2005 found that Agomelatine exhibited potential anxiety-relieving properties in rats. These anxiolytic effects were comparable to those induced by clorazepate, a clinically approved compound for treating anxiety, despite having a different mechanism of action. [R]
Recent research has further demonstrated the potential of Agomelatine in relieving anxiety. It was observed that Agomelatine blocks the 5HT2C receptor in nerve cells, which may contribute to anxiety while activating the MT receptor known for its anxiety-regulating effects. These findings indicate that Agomelatine’s anxiolytic effects operate through mechanisms distinct from other prescribed drugs for General Anxiety Disorder (GAD). [R]
Agomelatine and Sleep
An analysis of Agomelatine’s effects on sleep suggests that this antidepressant potentially brings about subjective and objective improvements in sleep. It may increase slow-wave sleep, enhance sleep wave quality, and have minimal impact on REM sleep. [R]
When taken at night, Agomelatine potentially improves sleep quality by mimicking the natural rhythm of melatonin release. It also has the potential to restore non-rapid-eye movement-rapid-eye movement (NREM-REM) sleep stage cycles during nighttime sleep.
Agomelatine has shown the potential to improve various aspects of the sleep-wake cycle in depressed test subjects. It demonstrated early effects on sleep quality and daytime alertness within one week of randomized trials. [R]
Agomelatine and Autism
Agomelatine has demonstrated an ameliorative effect on behavioral, neurochemical, and blood-brain barrier alterations in animal models of autism spectrum disorder (ASD). This suggests a potential therapeutic strategy for managing ASD. [R]
Furthermore, Agomelatine may potentially help reduce sleep disturbances in adults with ASD. A randomized clinical trial involving 25 adults with ASD found that Agomelatine administration for three months led to a reduction in sleep disturbances compared to a placebo group. [R]
A case study reported that a 3-week Agomelatine treatment reduced hyperactivity, irritability, and sleep pattern disturbances in a 10-year-old child with ASD. The positive response was maintained at weeks 6 and 12, indicating the potential of Agomelatine in addressing behavioral aspects of ASD. [R]
Agomelatine and Chronic Kidney Disease
In a rat model, Agomelatine exhibited protective effects against obesity-induced renal injury and renal dysfunction by ameliorating insulin resistance. It accomplished this by modulating oxidative stress, apoptosis (cell death), and ER stress, thereby improving renal function. These findings suggest a potential therapeutic role for Agomelatine in managing chronic kidney disease. [R]
Agomelatine and Neurogenesis
Neurogenesis, the process of generating new nerve cells in the brain, plays a crucial role in cognitive functioning, neural plasticity, and repair of damaged brain cells. Animal studies have provided evidence that Agomelatine may promote adult hippocampal neurogenesis in chronically stressed rats, suggesting a potentially positive impact on brain health. [R][R][R]
How It Works
Agomelatine exerts its mechanism of action by binding to melatonin receptors (MT1 and MT2), potentially leading to the stimulation of melatonin release. In addition, it acts as an antagonist of serotonin receptors (5HTC), which may result in the release of norepinephrine and dopamine, while not affecting serotonin levels.
These unique mechanisms differentiate Agomelatine from conventional antidepressants, which primarily act through monoaminergic pathways. While most antidepressants in the market target monoamine mechanisms, Agomelatine primarily acts via the melatonergic and serotonergic pathways.
This distinction in mechanism is significant and has been supported by a report from the European Medicines Agency (EMA) and a meta-analysis of 20 trials. These sources suggest that Agomelatine carries a relatively lower risk of severe side effects compared to standard antidepressants.
When researching the use of Agomelatine, it is essential to take certain precautions. Here are some precautions to keep in mind:
Observe best practices for studying research chemicals: Studying research chemicals requires a responsible and informed approach to ensure safety and meaningful scientific exploration. Research chemicals, also known as designer drugs or experimental compounds, are substances synthesized for scientific investigation or exploration of their properties.
Follow recommended dosage: Adhere to the recommended dosage instructions outlined on the product label to avoid a missed dose in your clinical studies. Avoid exceeding the suggested dose to minimize the risk of potential adverse effects among test subjects.
Potential Side Effects
Adverse reactions to Agomelatine may potentially include abdominal pain, insomnia, drowsiness, dizziness, and a potential increase in body weight. Some studies suggest, that certain people from countries where Agomelatine is prescribed, should avoid drinking alcohol when taking this research chemical.
Studies have not found any evidence of significant interactions between Agomelatine and other selective serotonin reuptake inhibitors (SSRIs) or therapeutic compounds when used concurrently.
In conclusion, recent studies about Agomelatine have shown some positive results in that could suggest its efficacy and safety as an atypical antidepressant. Its unique mechanism of action, which involves binding to melatonin receptors and inhibiting serotonin receptors, sets it apart from other commonly prescribed antidepressants that act through monoaminergic pathways.
The possible benefits of using Agomelatine could be plentiful. It has demonstrated the potential to improve sleep patterns and restore the circadian rhythm, making it a valuable option for individuals with sleep-related disturbances. Moreover, Agomelatine’s effectiveness in treating major depressive disorder has been supported by placebo-controlled trials, showcasing its potential as a reliable antidepressant.
When buying Agomelatine from an online pharmacy, we suggest examining if batch-specific analytical results are provided on each certificate of analysis. When considering Agomelatine for research, it is important to be mindful of potential drug interactions.
In your research, calculate the molar mass or batch-specific molecular weight of Agomelatine, using unified atomic mass units and the chemical formula, which can assist in determining the appropriate dosage and dilution required.
It is worth noting that Agomelatine may be associated with certain side effects, including weight gain.
Please take note of the scientific applications of this product and carefully read our Terms and Conditions before making a purchase from RCD.bio. By completing your order and submitting payment, you agree to abide by the Terms and Conditions of our company. Please be aware that the product packaging may differ slightly from the images displayed on our website.
If for any reason you are not completely satisfied with the product you receive, please contact us at [email protected]. Our team is dedicated to ensuring satisfaction among our customers.
PLEASE NOTE: All products offered by RCD.bio are strictly intended for laboratory and research purposes only. They are not intended for use on animals or humans.